source
- Yale and Harvard faculty question benefits of FDA's 'America First' user fee provisionsYale and Harvard medical school faculty have voiced concerns about the latest FDA user fee agreement, which includes a set of "America First" provisions. The provisions are designed to prioritize…
- Novartis stops ALS TREM2 stabilizer after Phase 2 miss, marking fourth trial setback in a monthNovartis has halted development of its TREM2 stabilizer VHB937, also known as lifonebart, for amyotrophic lateral sclerosis after the drug failed to meet either the primary or secondary endpoints i…